🇪🇸 Spanish Ferrer Internacional, SA has acquired the ex-US rights to an ALS treatment for €122.5m. 🧪 The treatment, VRG50635, is currently in Phase I trials and is believed to improve the survival of neurons in ALS patients. 💰 The deal includes upfront and milestone payments as well as royalties.
📢 Spanish Company Pays €1225m for ALS Treatment
Introduction:
Spanish Ferrer Internacional, SA has acquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialize the oral Phase I experimental ALS treatment. The deal includes upfront and milestone payments plus royalties.
Main points:
- Ferrer has acquired the ex-US rights to VRG50635, an experimental ALS treatment, from Verge Genomics Inc.
- VRG50635 is currently being tested in a Phase Ib trial and is believed to improve the survival of neurons in ALS patients.
- Ferrer’s previous Phase III oral ALS formulation of edaravone, called ADORE-ALS, failed in a phase III trial.
- Riluzole is currently the only approved treatment option for ALS in Europe.
- Verge Genomics’ AI platform, Converge, was used to develop VRG50635 by integrating human omics data, in vitro testing data, and clinical data from ALS patients and controls.
Conclusion:
Ferrer’s acquisition of VRG50635 from Verge Genomics Inc provides hope for an effective ALS treatment. The failure of Ferrer’s previous ALS formulation highlights the need for more research and development in this field. Verge Genomics’ AI platform demonstrates the potential for integrating diverse data sources to identify promising drug candidates.
